ArticleJMIR research protocols2026
The Role of MicroRNAs and Other Molecular Biomarkers in Uveitis: Protocol for a Scoping Review.
Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of MicroRNAs and Other Molecular Biomarkers in Uveitis: Protocol for a Scoping Review.JMIR research protocols · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUveitis is a complex disease involving inflammation of the iris, ciliary body, and choroid. The Standardization of Uveitis Nomenclature working group has developed classification criteria for 25 of the most common uveitis entities based on a number of descriptor terms. Due to the broad range of causes of uveitis and the different treatment modalities depending on etiology, investigative aids are vital in expediting accurate diagnosis and management. MicroRNAs, small noncoding RNAs, have exciting potential as biomarkers of disease. They function to alter gene expression at the posttranscriptional level. Other biomarkers of inflammatory disease include cytokines and chemokines. With a substantial proportion of uveitis being classified as "idiopathic," biomarker research may provide important diagnostic clues and subsequently improve patient outcomes globally. Scoping reviews represent a format for systematically searching the literature. We will use a formal framework for conducting scoping reviews and the Joanna Briggs Institute guidelines.
objectiveThe aim of this review protocol is to lay the foundation for identifying what biomarkers have been studied in various uveitis subtypes, including cytokines, chemokines, and multiomic data, with particular focus on microRNAs, thus guiding the selection of biomarkers that may be of interest in future research.
methodsStudies will be included if they have human participants with a defined diagnosis of a uveitis subtype who are of any age, gender, or ethnicity and from any country or health care setting; assess molecular biomarkers (including but not limited to microRNAs, cytokines, chemokines, human leucocyte antigen types, gene variants, and multiomics) using any sample type (including but not limited to blood, peripheral blood mononuclear cells, aqueous humor, vitreous humor, cerebrospinal fluid, and urine), are primary research studies, are written in English or with an English translation, and were published in any year. Studies will be excluded if they have animal participants, investigate therapeutics in uveitis only, are review articles or letters to the editor, are research in progress, or are not in English. The MEDLINE, Embase, and Scopus databases will be searched from inception to June 8, 2026. Results will be descriptively analyzed and presented in the form of a data extraction chart.
resultsThe proposed scoping review is currently in the screening stage. The start date for this project was January 6, 2026. The projected completion date is in October 2026. A total of 946 articles were subject to title and abstract screening using Covidence software. One reviewer screened all papers, while a second reviewer screened 20% of the papers.
conclusionsThe findings from this scoping review will highlight the broad range of molecular biomarkers currently studied in uveitis and identify gaps in the field, guiding the selection of biomarkers, with a particular focus on microRNAs, for future laboratory analysis in our research group.
trial registrationOSF Registries N5HJR; https://osf.io/n5hjr/overview. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/89265.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.